Odetiglucan(Odetiglucan) - 药物靶点：CD11b x CD32A x CLEC7A_在研适应症：结直肠癌肝转移，转移性结直肠癌，乳腺癌_专利_临床

概要

基本信息

药物类型

聚合物

别名

Betafectin、Imprime、Imprime PGG

+ [4]

靶点

CD11b x CD32A x CLEC7A

作用方式

激活剂、调节剂、刺激剂

作用机制

CD11b激活剂(integrin subunit alpha M activators)、CD32A激活剂(低亲和力免疫球蛋白γFc区受体II-a激活剂)、CLEC7A modulators(C-type lectin domain containing 7A modulators)

治疗领域

肿瘤消化系统疾病皮肤和肌肉骨骼疾病

在研适应症

结直肠癌肝转移转移性结直肠癌乳腺癌

非在研适应症

晚期头颈部鳞状细胞癌晚期非小细胞肺癌Vater壶腹癌+ [12]

原研机构

Biothera Pharmaceuticals, Inc. (Delaware)

在研机构

Merck Sharp & Dohme LLC

HiberCell, Inc.

非在研机构-

权益机构

HiberCell, Inc.

AstraZeneca PLC

Biodesix, Inc.

+ [1]

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

20

项与 Odetiglucan 相关的临床试验

NCT07082439

/ Not yet recruiting临床2期IIT

Phase II Trial of Pembrolizumab in Combination With Odetiglucan for Patients With Metastatic Colorectal Adenocarcinoma With Liver Predominant Disease

This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.

开始日期2025-07-01

申办/合作机构

Abramson Cancer Center

[+1]

NCT05484011

/ Terminated临床1期

P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo

The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of odetiglucan in combination with CDX-1140 in patients with metastatic PDAC with evidence of response or stable disease following a minimum of 16 and no more than 32 weeks of chemotherapy.
Up to 45 patients will be enrolled and dosed (30 patients in Part A and 15 in Part B).

开始日期2022-12-15

申办/合作机构

HiberCell, Inc.

[+1]

NCT05159778

/ Completed临床2期

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level (ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20 mcg/ml and meeting all other I/E criteria, will be enrolled.
The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more patients in Stage 1 have an objective response after 12 weeks of treatment, the study will proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined population of 47. Overall, objective responses must be observed in 10 patients for the study to be declared a success.

开始日期2021-11-09

申办/合作机构

HiberCell, Inc.

[+1]

100 项与 Odetiglucan 相关的临床结果

登录后查看更多信息

100 项与 Odetiglucan 相关的转化医学

登录后查看更多信息

100 项与 Odetiglucan 相关的专利（医药）

登录后查看更多信息

15

项与 Odetiglucan 相关的文献（医药）

2024-11-01·Translational Lung Cancer Research

Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017

Article

作者: Furqan, Muhammad ; Liu, Li ; Malhotra, Jyoti ; Feldman, Lawrence ; Hulbert, Alicia ; Shergill, Ardaman ; Mott, Sarah L ; Kennedy, Kathleen ; Pasquinelli, Mary M

Background:

Therapeutic strategies to engage anti-tumor innate immunity are still underdeveloped. Imprime PGG (imprime), a pathogen-associated molecular pattern (PAMP), through pattern recognition receptors, successfully illicit a broad-based innate immune response in preclinical models against various cancers. We aimed to study safety and efficacy of imprime in combination with pembrolizumab in advanced stage non-small cell lung cancer (NSCLC).

Methods:

We conducted an investigator-initiated, multi-institutional, single-arm, phase Ib/II trial in previously treated, advanced stage NSCLC patients. Primary endpoints were maximum-tolerated dose (MTD) of imprime for the phase Ib, and progression-free survival (PFS) for the phase II study (NCT03003468).

Results:

All 33 eligible patients were included in the safety analysis. No dose-limiting toxicity was observed and the imprime dose of 4 mg/kg was determined as the MTD. Thirty patients treated at the MTD (phase Ib, 6; phase II, 24) were included in the efficacy analysis. Median length of follow-up was 10.8 months. Confirmed objective response rate was 10% [95% confidence interval (CI): 2-27%], with one complete and two partial responses. Median PFS was 2.6 months (95% CI: 1.4-7.0), and 6- and 12-month PFS rates were 37% and 17%, respectively. Median overall survival (OS) was 11.1 months, and 6- and 12-month OS rates were 75% and 46%. Univariate analysis was performed to assess the impact of age, sex, race, disease-stage, programmed death-ligand 1 (PD-L1) expression levels, and prior immunotherapy on PFS and OS. Of these, prior immunotherapy negatively influenced OS [hazard ratio (HR): 2.95, 95% CI: 1.21-7.24]. Overall, the combination was safe and tolerable.

Conclusions:

The combination of imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage NSCLC patients who previously progressed on anti-programmed death 1 (PD-1)/PD-L1 immunotherapies. Further investigation is needed to understand the effects of therapeutic PAMPs to mount a strong innate immune response against cancer.

2020-03-01·Anticancer research4区 · 医学

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

4区 · 医学

Article

作者: Jha, Gautam ; Qiu, Xiaohong ; Gorden, Keith ; Hurley, Peter J ; Gargano, Michele ; Bose, Nandita ; Rathmann, Blaine ; Ottoson, Nadine ; Harrison, Ben ; Dudek, Arkadiusz Z

BACKGROUND:

BTH1677 is a beta-glucan pathogen-associated molecular pattern (PAMP) being evaluated as a novel immunotherapy of cancer. We previously described that the presence of antibodies against beta-glucan (ABA) in serum is necessary for BTH1677 antitumoral activity. We hypothesized that infusion of immunoglobulin can reinstate responses to BTH1677 in individuals with low ABA levels.

PATIENTS AND METHODS:

We report two single-patient studies: one in a patient with metastatic colorectal cancer who received BTH1677, combined with tumor targeting antibody cetuximab; and a second in a patient with metastatic neuroendocrine tumor who received BTH1677 combined with immune checkpoint inhibitor pembrolizumab.

RESULTS:

The patients had low serum titers of ABA and low innate immune effector functionality induced by BTH1677. Addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoral activity, with long-term disease control.

CONCLUSION:

Infusion of immunoglobulin can restore activity of BTH1677 in individuals with low serum ABA level.

2019-05-15·Journal of immunology (Baltimore, Md. : 1950)2区 · 医学

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

2区 · 医学

Article

作者: Harrison, Ben ; Fulton, Ross B ; Bose, Nandita ; Jordan, Lindsay R ; Fraser, Kathryn A ; Ottoson, Nadine R ; Graff, Jeremy R ; Qiu, Xiaohong ; Ertelt, Kathleen E ; Gorden, Keith B ; Jonas, Adria Bykowski ; Uhlik, Mark T ; Kangas, Takashi O ; Chan, Anissa S H ; Matson, Mark A ; Huhn, Richard D ; Leonardo, Steven M ; Lowe, Jamie R ; Walsh, Richard M ; Rathmann, Blaine T

Abstract:

Imprime PGG (Imprime) is an i.v. administered, yeast β-1,3/1,6 glucan in clinical development with checkpoint inhibitors. Imprime-mediated innate immune activation requires immune complex formation with naturally occurring IgG anti-β glucan Abs (ABA). We administered Imprime to healthy human volunteers to assess the necessity of ABA for Imprime-mediated immunopharmacodynamic (IPD) changes. Imprime (4 mg/kg) was administered i.v. in single and multiple infusions. Subsets of subjects were premedicated with antihistamine and corticosteroid. Peripheral blood was measured before, during and after Imprime administration for IPD changes (e.g., ABA, circulating immune complexes, complement activation, complete blood counts, cytokine/chemokine, and gene expression changes). IPD changes were analyzed based on pretreatment serum ABA levels: low-ABA (<20 μg/ml), mid-ABA (≥20–50 μg/ml), and high-ABA (≥50 μg/ml). At the end of infusion, free serum ABA levels decreased, circulating immune complex levels increased, and complement activation was observed. At ∼1–4 h after end of infusion, increased expression of cytokines/chemokines, a 1.5-4-fold increase in neutrophil and monocyte counts and a broad activation of innate immune genes were observed. Low-ABA subjects typically showed minimal IPD changes except when ABA levels rose above 20 μg/ml after repeated Imprime dosing. Mild-to-moderate infusion-related reactions occurred in subjects with ABA ≥20 μg/ml. Premedications alleviated some of the infusion-related reactions, but also inhibited cytokine responses. In conclusion, ABA levels, being critical for Imprime-mediated immune activation may provide a plausible, mechanism-based biomarker to identify patients most likely to respond to Imprime-based anticancer immunotherapy.

9

项与 Odetiglucan 相关的新闻（医药）

2024-10-23

·BioSpace

HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA’s Fast Track program aims to facilitate the development, and expedite the review, of novel potential therapies that are designed to treat serious conditions and have the potential to address significant unmet medical need. “We are proud to announce the grant of Fast Track designation by the FDA,” said Jonathan Lanfear, President & CEO of HiberCell. Receiving Fast Track designation highlights the FDA’s recognition of the robust preclinical data generated to date for HC-7366 and the potential for HC-7366 to address the significant unmet need that exists in R/R AML.” Mr. Lanfear continued, “HC-7366 was the first GCN2-activator to enter the clinic in AML and is the only GCN2-targeting agent to receive Fast Track designation for the treatment of AML, validating our preclinical and translational efforts. We plan to leverage the Fast-Track designation to work closely with the FDA to facilitate and, potentially accelerate the development of HC-7366 in AML.” HC-7366 is currently under clinical investigation in both solid and liquid tumor settings. The Phase 1b study in AML (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in relapsed/refractory (R/R) AML or MDS AML. This study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in a R/R AML population. Dependent on observations in the dose escalation portion, this study may include additional combination and monotherapy expansions. About HC-7366 HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with standard of care agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in R/R AML (NCT06285890). About HiberCell HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. For Media/Investor Inquiries: IR@hibercell.com

临床1期快速通道临床2期

2024-05-29

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

May 28, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML). "We are excited to announce the first patient dosed in this study," said Jonathan Lanfear, President & CEO of HiberCell. "This study builds on the preclinical data we have presented at recent conferences, including the 2023 ASH Annual Meeting and Exposition, which support evaluation of HC-7366 in combination with venetoclax and azacitidine in AML patients with significant unmet need." The study’s principal investigator is Dr. Abhishek Maiti, assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. Mr. Lanfear continued, "The initiation of this study along with our recently announced study of HC-7366 in clear cell renal cell carcinoma marks the continued advancement of HC-7366 and HiberCell. These are seminal combinatorial studies of HC-7366 with the potential to address large, targeted, and underserved patient populations. We look forward to seeing data for these studies throughout 2024 and 2025." The newly announced Phase 1b study (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with standard dosing of venetoclax and azacitidine in patients with relapsed/refractory (R/R) AML or MDS AML. The study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in combination with venetoclax and azacitidine in a R/R AML population. The study will enroll up to 18 patients. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in AML in combination with azacitidine and venetoclax (NCT06285890). HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床研究临床2期

2024-05-02

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

May 01, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The Phase 1b study (NCT06234605) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with belzutifan in patients with advanced ccRCC. This trial will also determine a recommended Phase 2 dose (RP2D) of HC-7366 in combination with fixed-dose belzutifan, 120 mg po qd. Dose escalation of HC-7366 in the combination, followed by an expansion phase will optimize dose evaluation. An independent HC-7366 monotherapy cohort is being evaluated in parallel. The study will enroll up to 80 patients at clinical sites across the US. Robert J. Motzer, MD., Section Head, Kidney Cancer, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) will be the lead Principal Investigator (PI) for the clinical trial. "The first patient dosed in this trial marks the beginning of an exciting new chapter in the clinical development of HC-7366," stated Cherry Thomas, M.D., Chief Medical Officer. "The combination of HC-7366 with belzutifan, a key agent for the treatment of clear cell renal cell carcinoma, offers a potentially promising novel and differentiated treatment in a setting with major unmet need and limited treatment options for patients. We recently presented key aspects of the significant preclinical data in support of the combination at the 2024 American Association for Cancer Research Annual Conference." WELIREG® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in preclinical models of both solid and liquid tumors. HC-7366 is currently under clinical development in a Phase 1b study in clear cell renal cell carcinoma in combination with belzutifan. HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床2期AACR会议

100 项与 Odetiglucan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
KRAS 野生型结直肠癌	临床3期	美国	HiberCell, Inc.	2011-04-01
KRAS 野生型结直肠癌	临床3期	法国	HiberCell, Inc.	2011-04-01
KRAS 野生型结直肠癌	临床3期	德国	HiberCell, Inc.	2011-04-01
KRAS 野生型结直肠癌	临床3期	波多黎各	HiberCell, Inc.	2011-04-01
结直肠癌肝转移	临床2期	美国	Merck Sharp & Dohme LLC	2025-07-01
转移性结直肠癌	临床2期	美国	Merck Sharp & Dohme LLC	2025-07-01
乳腺癌	临床2期	-	HiberCell, Inc.	2022-04-28
转移性乳腺癌	临床2期	美国	HiberCell, Inc.	2021-11-09
晚期头颈部鳞状细胞癌	临床2期	美国	HiberCell, Inc.	2017-11-08
转移性非小细胞肺癌	临床2期	美国	HiberCell, Inc.	2017-07-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00545545 (CTgov)	临床1/2期	复发性结直肠癌 \| 结直肠癌	32	PGG+Cetuximab+Irinotecan (Arm 1, Imprime PGG Injection 2 mg/kg+ Cetuximab + Irinotecan)	鹹獵鹹顧鏇齋顧夢網糧 = 築製積鏇製鹹齋範積壓網蓋鑰選廠繭艱廠醖餘 (膚鹹獵艱顧艱餘窪顧餘, 觸積壓壓憲憲鏇獵網襯 ~ 簾顧膚窪獵簾夢醖艱遞) 更多	-	2025-03-19
				PGG+Cetuximab+Irinotecan (Arm 1, Imprime PGG Injection 4 mg/kg+ Cetuximab + Irinotecan)	鹹獵鹹顧鏇齋顧夢網糧 = 範襯膚憲鹽簾鏇壓齋獵網蓋鑰選廠繭艱廠醖餘 (膚鹹獵艱顧艱餘窪顧餘, 網鑰醖鹹遞範鏇蓋範糧 ~ 醖鬱艱遞範艱艱選艱願) 更多
NCT03003468 (BTCRC LUN 15-017, Pubmed \| Transl Lung Cancer Res)	临床1/2期	非小细胞肺癌	33	Imprime PGG 4 mg/kg + Pembrolizumab	構餘襯網鹹積獵衊鹹獵(簾願鏇製鹹壓壓鹹餘醖) = 獵餘製繭醖齋艱積蓋選夢網膚齋遞鏇膚鏇鬱獵 (遞鹽艱艱願網構衊窪獵 ) 更多	不佳	2024-11-01
NCT03003468 (BTCRC-LUN15-017 \| BTCRC LUN 15-017, CTgov)	临床1/2期	转移性非小细胞肺癌	35	Imprime PGG+pembrolizumab (Phase Ib)	壓鬱窪襯廠鹽顧遞艱醖 = 製選餘壓糧繭壓膚選網夢觸窪願鏇構鑰廠選獵 (選壓壓廠窪窪顧齋顧構, 蓋蓋膚膚齋築網鹹築遞 ~ 簾膚餘廠餘繭廠廠選衊) 更多	-	2024-08-13
				PGG (Imprime PGG 4 mg/kg)	觸鑰積積廠鬱鬱糧鏇鏇(構網膚簾網顧憲糧鑰糧) = 襯齋選窪襯齋鹽築網餘餘網壓範鹽鑰獵網築糧 (願選鏇齋製觸窪遞醖鹹, 窪鹹艱壓觸網壓鹹鏇廠 ~ 鑰廠憲顧獵鬱網糧憲糧) 更多
NCT02981303 (Phase 2 \| IMPRIME 1, CTgov)	临床2期	肝转移 \| 肿瘤转移 \| 三阴性乳腺癌 ... 更多	64	Imprime PGG+Pembrolizumab (Melanoma)	蓋願蓋齋積鏇膚壓夢蓋(觸範齋獵鬱觸壓鏇築製) = 膚窪齋繭構艱蓋願窪範蓋淵淵鑰鹹憲鬱範膚壓 (構淵憲範蓋網艱鬱憲範, 網餘網鬱衊淵顧簾觸製 ~ 襯繭憲廠選積艱鬱憲醖) 更多	-	2024-07-09
				Imprime PGG+Pembrolizumab (Triple Negative Breast Cancer)	蓋願蓋齋積鏇膚壓夢蓋(觸範齋獵鬱觸壓鏇築製) = 顧窪鬱窪糧顧艱糧憲簾蓋淵淵鑰鹹憲鬱範膚壓 (構淵憲範蓋網艱鬱憲範, 繭繭襯繭襯淵窪襯齋獵 ~ 簾夢鏇遞獵夢獵網鑰積) 更多
NCT05159778 (ASCO2022)	临床2期	转移性乳腺癌	47	Odetiglucan 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	糧築衊積襯齋淵糧餘餘(選積鹹鹹襯製艱襯窪繭) = 簾製鏇網襯積觸築膚襯鹽簾範網襯積獵憲願鏇 (淵遞簾憲襯鹹壓選廠範 ) 更多	-	2022-06-02
Abstract OT1-18-05 (SABCS2022)	临床2期	转移性乳腺癌 PD-L1-positive	47	Imprime PGG 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	鏇衊壓衊願構觸廠壓夢(築艱築範蓋簾鑰廠選蓋) = 鹽襯顧壓鏇觸蓋鹹選顧蓋夢鹽醖憲餘窪窪糧憲 (蓋艱遞選築糧餘糧鏇網 ) 更多	积极	2022-02-15
NCT03003468 (BTCRC-LUN15-017, WCLC2021 \| WCLC2021) 人工标引	临床1/2期	非小细胞肺癌	35	Pembro+Imprime PGG (phase Ib)	鏇製鹹醖鏇鏇選遞觸範(繭艱夢窪構簾顧鑰淵鏇) = 選願齋齋壓鹹廠廠範廠構廠憲願網襯顧願鏇醖 (壓艱憲鹹膚製製網憲齋, 1.28 ~ 27.8) 更多	不佳	2021-09-08
				Pembro+Imprime PGG (phase II)	鏇製鹹醖鏇鏇選遞觸範(繭艱夢窪構簾顧鑰淵鏇) = 餘鏇蓋齋願觸繭製艱廠構廠憲願網襯顧願鏇醖 (壓艱憲鹹膚製製網憲齋, 1.35 ~ 5.13) 更多
NCT02086175 (CTgov)	临床2期	难治性惰性非霍奇金淋巴瘤 \| 复发性惰性非霍奇金淋巴瘤	25	Imprime PGG+Rituximab	淵齋鹹願範願網願鬱齋 = 淵廠醖襯夢膚餘蓋艱窪繭窪廠艱鬱遞築憲糧淵 (壓淵齋選餘簾製糧鬱網, 鏇壓鑰觸顧衊觸鏇夢糧 ~ 齋鏇範願淵鑰夢築製繭) 更多	-	2021-01-07
NCT02981303 (IMPRIME 1, AACR2020)	临床2期	转移性三阴性乳腺癌	44	Imprime PGG + Pembrolizumab	艱獵膚襯壓鑰鑰積鑰獵(網願餘遞繭壓鏇膚積遞) = 積艱窪窪糧選夢襯願構網壓窪艱積簾鑰齋淵淵 (獵積顧繭觸廠遞淵簾願, 7.9 ~ 29.4) 更多	积极	2020-08-15
NCT01269385 (CTgov)	临床1/2期	难治性慢性淋巴细胞白血病	22	PGG beta-glucan+Rituximab+Alemtuzumab (Phase I: Dose Level 0)	窪鬱衊憲簾鑰鹹積餘繭 = 範夢糧醖鹹糧鹽膚艱網鑰製蓋壓壓壓鹽願選築 (顧網壓膚糧顧構製遞簾, 願繭窪憲齋醖窪襯衊願 ~ 淵膚觸壓蓋網選簾願構)	-	2020-06-23
				PGG beta-glucan+Rituximab+Alemtuzumab (Phase I: Dose Level 1)	窪鬱衊憲簾鑰鹹積餘繭 = 鹽壓鬱鏇窪艱廠遞醖遞鑰製蓋壓壓壓鹽願選築 (顧網壓膚糧顧構製遞簾, 鑰壓簾餘範醖獵憲範繭 ~ 繭築製齋夢蓋衊艱蓋衊)